Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...

To read last Friday’s edition of Five things for pharma marketers to know, click here.